Canakinumab

Details

Files

Generic Name:

Canakinumab

Project Status:

Complete

Therapeutic Area:

Systemic Juvenile Idiopathic Arthritis

Manufacturer:

Novartis Pharmaceuticals Inc.

Call for patient/clinician input open:

November 24, 2015

Brand Name:

Ilaris

Project Line:

Reimbursement Review

Project Number:

SR0463-000

Call for patient/clinician input closed:

January 20, 2016

NOC Status at Filing:

Post NOC

Performance Metric:

Achieved

Submission Type:

Initial

Indications:

Systemic juvenile idiopathic arthritis

Recommendation Type:

Reimburse with clinical criteria and/or conditions

Final Recommendation:

June 17, 2016

Files

Submission Status Report View PDF

Clinical Report View PDF

Pharmacoeconomic Report View PDF

Recommendation and Reasons View PDF

Patient Group Input Submissions View PDF

Last Updated : November 24, 2015